MOLECULAR-GENETIC APPROACH FOR OPTIMIZATION OF MODERN ANTIAGGREGANT THERAPY
Abstract
The targets of application of antiaggregant therapy by clopidogrel and the factors that influence its outcome were presented, in this review. Special attention was given to the application of personalized, approach for the optimization of clopidogrel therapy. The data of clinical investigations were discussed.
About the Authors
N. YU. Knauer
Novosibirsk National Research State University
Russian Federation
Russian Federation
G. I. Lifshits
Institute of Chemical Biology and Fundamental Medicine SB RAS
Russian Federation
Russian Federation
References
1. Грацианский Н.А. Национальные рекомендации по лечению ОКС без стойкого подъема ST на ЭКГ // Кардиоваскулярная терапия и профилактика. - 2006. - Вып. 8, № 5. - С. 411-440.
2. Диагностика и лечение фибрилляции предсердий / А.Л. Сыркин, В.А. Сулимов, И.Г. Фомина [и др.] // Кардиоваскулярная терапия и профилактика. - 2005. - Вып. 4, № 4. - P. 475-508.
3. Национальные рекомендации по диагностике и лечению стабильной стенокардии / Р.С. Акчурин, Ю.А. Васюк, Ю.А. Карпов [и др.]. - М., 2009.
4. Ahmad T., Voora D., Becker R.C. The pharmacogenetics of antiplatelet agents: towards personalized therapy? // Nat. Rev. Cardiol. - 2011. - Vol. 8. -N 10. - P. 560-571.
5. Ambudkar S.V., Kim I.W., Sauna Z.E. The power of the pump: mechanisms of action of P-glycoprotein (ABCB1) // Eur. J. Pharm. Sci. - 2006. - Vol. 27, N 5. - P. 392-400.
6. Angiolillo D.J., Ferreiro J.L. Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions // Rev. Esp. Cardiol. - 2010. - Vol. 63, N 1. - P. 60-76.
7. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy / A.R. Shuldiner, J.R. O'Connell, K.P. Bliden [et al.] // J. Am. Med. Assoc. - 2009. -Vol. 302, N 8. - P. 849-857.
8. Chua D., Legal M., Shalansky S.J. Clopidogrel plus aspirin in atrial fibrillation // N. Engl. J. Med. - 2009. - Vol. 361, N 13. - P. 1312-1313.
9. Clopidogrel, haemorrhage and haematological disorders // WHO Drug Information. - 2004.
10. Clopidogrel: new use / Ed. C. Encrenaz // WHO Drug Information. - 2006. - P. 199.
11. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement / D. Sibbing, W. Koch, D. Gebhard, [et al.] // Circulation. - 2010. - Vol. 121, N 4. - P. 512-518.
12. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention / D. Sibbing, J. Stegherr, W. Latz [et al.] / Eur. Heart J. - 2009. - Vol. 30, N 8. - P. 916-922.
13. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents / D. Trenk, W. Hoch-holzer, M.F. Fromm [et al.] // J. Am. Coll. Cardiol. -2008. - Vol. 51, N 20. - P. 1925-1934.
14. Davi G., Patrono C. Platelet activation and ath-erothrombosis // N. Engl. J. Med. - 2007. - Vol. 357, N 24. - P. 2482-2494.
15. Effect of clopidogrel added to aspirin in patients with atrial fibrillation / S.J. Connolly, J. Pogue, R.G. Hart [et al.] // N. Engl. J. Med. - 2009. -Vol. 360, N 20. - P. 2066-2078.
16. Fromm M.F. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans // Adv. Drug. Deliv. Rev. - 2002. - Vol. 54, N 10. - P. 1295-1310.
17. Fuster V. Fine-tuning therapy for acute coronary syndromes // N. Engl. J. Med. - 2010. -Vol. 363, N 10. - P. 976-977.
18. Genetic determinants of response to clopidogrel and cardiovascular events / T. Simon, C. Verstuyft, M. Mary-Krause [et al.] // N. Engl. J. Med. - 2009. -Vol. 360, N 4. - P. 363-375.
19. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopi-dogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis / J.L. Mega, S.L. Mega, S.D. Wiviott [et al.] // Lancet. - 2010. - Vol. 376, N 9749. - P. 1312-1319.
20. Pisters R., Dinh T., Crijns H.J. Clopidogrel plus aspirin in atrial fibrillation // N. Engl. J. Med. - 2009. - Vol. 361, N 13. - P. 1312.
21. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives / D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo [et al.] // J. Am. Coll. Cardiol. -2007. - Vol. 49, N 14. - P. 1505-1516.
22. Variability in platelet responsiveness to clopidogrel among 544 individuals / V.L. Serebruany, S.R. Steinhubl, P.B. Berger [et al.] // J. Am. Coll. Cardiol. - 2005. - Vol. 45, N 2. - P. 246-251.
Review
For citations:
Knauer N.Yu., Lifshits G.I. MOLECULAR-GENETIC APPROACH FOR OPTIMIZATION OF MODERN ANTIAGGREGANT THERAPY. Acta Biomedica Scientifica. 2012;(2(1)):143-152. (In Russ.)
Views:
334
Email this article 
